# BCB-276

Source: https://onco.cc/drugs/bcb-276/  
OnCo record `bcb-276` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BCB-276 is an experimental CAR-T cell therapy from BrainChild Bio in phase 2 trials for glioma & glioblastoma, aimed at B7-H3.

## Summary

BCB-276 is a CAR-T cell therapy developed by BrainChild Bio. Its target is B7-H3 (the sponsor names B7-H3). The sponsor states: An autologous CAR T-cell therapy targeting B7-H3, an antigen described as universally expressed in diffuse intrinsic pontine glioma (DIPG), manufactured from the patient's own leukapheresed immune cells after standard radiation therapy. ClinicalTrials.gov describes the intervention as: Following completion of standard radiation therapy, eligible participants with DIPG will undergo leukapheresis, a procedure to collect white blood cells used to manufacture BCB-276, an autologous CAR T cell therapy made from the participant. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in glioma & glioblastoma. The largest, NCT07680439, plans to enrol 75 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: An autologous CAR T-cell therapy targeting B7-H3, an antigen described as universally expressed in diffuse intrinsic pontine glioma (DIPG), manufactured from the patient's own leukapheresed immune cells after standard radiation therapy.

## Sources

- ClinicalTrials.gov: trials of BCB-276: https://clinicaltrials.gov/search?intr=BCB-276
- Sponsor pipeline page: https://brainchildbio.com/pipeline/

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/)
- trials: [Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).](https://onco.cc/trials/nct07680439/)

---
JSON: https://onco.cc/api/v1/entities/bcb-276.json